A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
A phase 1/2 trial of Erdafitinib, Cetrelimab, Cisplatin and Carboplatin in bladder & urothelial cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
Overview
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer is a phase 1/2 interventional study registered as NCT03473743 by Janssen Research & Development, LLC, with 125 participants enrolled, started 2018-04-05 and due to reach its primary completion in 2022-09-30. Interventions recorded: Erdafitinib, Cetrelimab, Cisplatin and Carboplatin. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialAn Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Shares Erdafitinib, Johnson & Johnson, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Shares Erdafitinib, Johnson & Johnson, Bladder & urothelial cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Shares Cetrelimab, Johnson & Johnson and the tag pipeline.
- TrialA Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
Shares Cetrelimab, Johnson & Johnson and the tag pipeline.
- TrialPhase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Shares Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Shares Johnson & Johnson, Cisplatin, Carboplatin and the tag pipeline.
- Trial9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Shares Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Shares Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.